US drug firms Abbott and Enanta have moved their jointly developed hepatitis C (HCV) drugs to Phase II clinical trials.
The trial will evaluate three HCV antiviral agents, ABT-450, ABT-333 and ABT-072.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ABT-450, an investigational protease inhibitor, is part of the Abbott-Enanta collaboration while the polymerase inhibitors ABT-333 and ABT-072 are being developed by Abbott.
The Phase II trials are aimed at assessing the antiviral activity, pharmacokinetics, safety and tolerability of multiple dose strengths of ABT-450, ABT-333 and ABT-072, dosed individually in treatment-naïve adults infected with HCV genotype 1.
Initial antiviral activity will be evaluated over a three-day monotherapy period and subsequently each antiviral agent will be administered with pegIFN/RBV for 12 weeks, followed by treatment with standard of care alone for an additional 36 weeks.
The trial participants will then be monitored for sustained virologic response.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHepatitis C affects 170 million people worldwide.
